KROS שיעור רווח גולמי Keros Pharma

Keros Therapeutics (KROS) leverages bioinformatics and AI to accelerate the discovery of therapeutic molecules. The gross margin on the GURU.Markets chart demonstrates an efficiency trend, where the current metric equals 96.10. The company focuses on TGF-beta regulators for lung and blood therapies, diversifying its pipeline. Business success depends on clinical trials, remaining independent of economic cycles, except for capital liquidity risks.
פילוחי מדדים פיננסיים ומדדי שוק עבור Keros Therapeutics Inc (KROS)

To objectively evaluate the issuer, it is essential for the manager to understand the portion of revenue remaining after deducting direct production costs, which allows the financial result to be stripped of accounting conventions. Analyzing the gross margin helps identify hidden expense anomalies, which is critical for Keros Therapeutics (KROS) when financing late-stage clinical trials for drugs targeting muscle and hematological pathologies.